Alicja Dębska-Ślizień
Alicja Dębska-Ślizień is an expert in Surgery at University Clinical Centre (Poland). As of October 2026, ScienceLeadR ranks Alicja Dębska-Ślizień in the top 1% of experts worldwide for Kidney Transplantation, and in the top 1% of experts in Poland for Coronavirus Infections and COVID-19. Alicja Dębska-Ślizień has authored 501 publications, the most recent in 2026, and is an investigator in 8 clinical trials, 4 of them ongoing. SLR score: 1,481 (community average: 125). How the SLR is computed.
LeadR Profile
Surgery
Subspecialties: Transplantation - Nephrology - Biochemistry
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2004 - 2026
Number : 501
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Familiarity With and Use of Clinical Prediction Models in Nephrology Practice in Poland. PMID 42860951 — risk assessment, nephrology, renal insufficiency, prognosis | Kidney Int Rep | 2026 | 0 |
| Isoprostanes as biomarkers of oxidative stress across human diseases and skin pathologies. PMID 42614219 — skin, stress, physiological, neoplasms, pathology, oxidative stress, biomarkers, transplants, research, transplantation, skin neoplasms, isoprostanes | Front Mol Biosci | 2026 | 0 |
| Urinary DNA Methylation and Hydroxymethylation Dynamics as Candidate Biomarkers of Occupational Chemical Exposure-An Exploratory Pilot Study. PMID 42511754 — pilot projects, pilots, occupational exposure, biomarkers, dna methylation, isocyanates, deoxyguanosine, deoxycytidine, dna, deoxyuridine | Int J Mol Sci | 2026 | 0 |
| Integrated immune profiling identifies a coordinated T-cell activation and inflammatory signature in SLE. PMID 42457337 — cells, genes, lupus erythematosus, systemic, therapeutics, t-lymphocytes, b-lymphocytes, infections | Lupus Sci Med | 2026 | 1 |
| Fracture risk assessment in early-stage autosomal dominant polycystic kidney disease: a cross-sectional study using FRAX ®, QFracture ®, and Garvan models. PMID 42387458 — kidney diseases, cross-sectional studies, risk assessment, kidney, polycystic kidney diseases, polycystic kidney, autosomal dominant | BMC Nephrol | 2026 | 0 |
Clinical Studies 8
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
4 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Phase 3 Study of Ravulizumab versus Placebo in Adult Participants at High Risk of DGF after Kidney Transplantation (AWAKE) 2024-517568-48-00 — safety, kidney, delayed graft function, transplants, kidney transplantation, transplantation | Phase 3 | Recruiting | 2025 |
| RemiRit Personalized immunosuppressive therapy with rituximab in the treatment of ANCA associated vasculitis a randomized multicenter clinical trial 2024-517881-40-00 — vasculitis, cyclophosphamide, genetic predisposition to disease, rituximab, anti-neutrophil cytoplasmic antibody-associated vasculitis, antibodies, antineutrophil cytoplasmic, therapeutics, immunosuppression therapy | Phase 2 | Active not recruiting | 2022 |
| Tacrolimus and Risk Factors for Glucose Metabolism Disorders in Kidney Transplant Patients NCT06833463 — diabetes mellitus, blood glucose, insulin, blood, sugars, kidney, tacrolimus, risk factors, transplants, therapeutics, glucose metabolism disorders | N/A | Recruiting | 2025 |
| Attitudes and Knowledge of Dialysis Patients Towards Kidney Transplantation NCT06148116 — kidney diseases, genes, pol, waiting lists, kidney, transplants, kidney transplantation, transplantation | N/A | Recruiting | 2023 |
LeadR Networks
Main global connection map